Breast Cancer Clinical Trials

Find Breast Cancer Clinical Trials Near You

Inflammatory and Neural Correlates of Chemotherapy-Induced Cognitive Impairment: A Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of chemo fog also known as chemobrain has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what chemobrain is, and what causes it, there is little that doctors can do to help at the moment. The team proposing this study believe that chemotherapy causes chemicals associated with inflammation to attack parts of the brain that are important for concentration and making new memories. Unfortunately, it is not possible to measure these chemicals directly in the brain, but we believe that a brain scan sensitive to excess iron, a marker of brain inflammation, can help. This project will measure thinking ability, such as memory and concentration, take a blood sample and do a brain scan before, during and after a patient has chemotherapy. We will then look for changes in iron in the brain areas that are important for concentration and memory and compare those to changes in thinking ability and to levels of inflammation chemicals in the blood. This information will be essential to help plan our next step which is to test ways to reduce the effects of chemobrain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Women and men \>18 years

• Diagnosed with HER2 negative breast cancer

• Receiving EC-Taxane or Taxane only based chemotherapy

• Able to communicate in English

• Willing and able to give informed consent for participation in the study.

Locations
Other Locations
United Kingdom
NHS Grampian
RECRUITING
Aberdeen
Contact Information
Primary
Teresa Morris
t.morris@abdn.ac.uk
+44 + 1224438363
Time Frame
Start Date: 2022-12-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Treatments
Patient
No intervention
Related Therapeutic Areas
Sponsors
Leads: University of Aberdeen
Collaborators: NHS Grampian

This content was sourced from clinicaltrials.gov